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DE ACORDO COM A LEGISLAÇÃO EM VIGOR, NÃO É PERMITIDA A 
REPRODUÇÃO DE QUALQUER PARTE DESTA DISSERTAÇÃO.
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“Learn from yesterday, live for today, hope for tomorrow. The 
important thing is not to stop questioning” 
                 Albert Einstein  
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Abstract 
Leishmaniasis is a worldwide disease caused by a digenetic protozoan parasite which 
can appear in different clinical forms, depending on the Leishmania species involved and 
the immune status of the host. It is the most important vector-borne disease after malaria 
and sleeping sickness. 
The main reservoir for human visceral leishmaniasis is the dog, Canis familiaris. 
Infected domestic dogs serve as reservoirs of the disease for people in several areas where 
leishmaniasis is endemic. Both dogs and humans are infected via the bite of female 
phlebotomine sandflies, which breed in forest areas, caves, or the burrows of small 
rodents. 
Leishmaniasis is a diagnostic challenge because of the wide spectrum of clinical 
manifestations that it may present. Visceral leishmaniasis is a fatal disease if untreated 
and the therapeutic success comes in line with an early detection of the disease. Thus, 
accurate diagnosis tests are needed, especially for the detection of asymptomatic patients. 
The perfect diagnosis methods should be easy to perform, not expensive and highly 
sensitive and specific. In this work, we explored ELISA based diagnosis tests for the 
accurate diagnosis of human VL. 
Key words: human leishmaniasis, ELISA, diagnosis. 
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Resumo 
A leishmaniose é uma doença do mundo, causada por um protozoário parasita que 
pode aparecer em diferentes formas clínicas, dependendo das espécies de Leishmania 
envolvidas e o estado imunológico do hospedeiro. É a mais importante doença transmitida 
por vetores após malária e a doença do sono.  
O principal reservatório para a leishmaniose visceral humana é o cão, Canis 
familiaris. Cães domésticos infetados servem como reservatórios da doença para os 
humanos em diversas áreas onde a doença é endémica. Tanto os cães e como os humanos 
são infetados através da picada de flebotomíneos do sexo feminino.  
A leishmaniose é um desafio a nível do diagnóstico, considerando o amplo espectro 
de manifestações clínicas que podem apresentar. A leishmaniose visceral é uma doença 
fatal se não tratada e o sucesso terapêutico depende da deteção precoce da doença. Assim, 
são necessários testes de diagnóstico precisos e exatos, especialmente para a deteção da 
doença em pacientes assintomáticos. O método de diagnóstico ideal deve ser fácil de 
executar, não ser caro e ser altamente sensível e específico. Neste trabalho, exploramos 
testes diagnósticos baseados no método de ELISA para o diagnóstico preciso da 
leishmaniose humana.  
Palavras-chave: leishmaniose humana, ELISA, diagnóstico. 
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I. Introduction 
 
Leishmaniasis is a vector-borne disease caused by protozoa of the genus Leishmania, 
family Trypanosomatidae and order Kinetoplastida(2). It is a worldwide disease caused by 
a digenetic protozoan parasite which can appear in different clinical forms, depending on 
the Leishmania species involved and the immune status of the host. It is the most 
important vector-borne disease after malaria and sleeping sickness (3, 4). There are three 
major clinical types of this infection: cutaneous (CL), mucocutaneous (MCL) and visceral 
(VL). VL,  also known as kala azar, is a severe infectious disease caused by L. donovani in 
East Africa and the Indian subcontinent and L. infantum in Latin America and the 
Mediterranean basin (5, 6) . 
The main reservoir for human VL is the dog, Canis familiaris. Infected domestic dogs 
serve as reservoirs of the disease for people in several areas where leishmaniasis is 
endemic. Canine leishmaniasis (CVL) is also sometimes found in non-endemic countries 
because of international tourists and immigrants who bring infected pets and dog 
importation from endemic areas. Dogs can be asymptomatic carriers of leishmaniasis 
maintaining this status for a long period of time, being nevertheless highly competent to 
transmit the parasite to sandflies (7) . Both dogs and humans are infected via the bite of 
female phlebotomine sandflies, which breed in forest areas, caves, or the burrows of small 
rodents (4, 7, 8). 
Leishmaniasis is a diagnostic challenge because of the wide spectrum of clinical 
manifestations that it may present. VL is a fatal disease if untreated and the therapeutic 
success comes in line with an early detection of the disease. Thus, accurate diagnosis tests 
are needed, especially for the detection of asymptomatic patients. The perfect diagnosis 
methods should be easy to perform, not expensive and highly sensitive and specific (3). In 
this work, we explored ELISA based diagnosis tests for the accurate diagnosis of human 
VL. 
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1.1 Transmission and life cycle 
 
Leishmania parasites are transmitted to mammals by the bite of female 
phlebotomine sand flies and occasionally by the sharing of needles, by blood 
transfusion, or by congenital transmission.  
There are two types of VL, which differ in their transmission characteristics: 
zoonotic VL is transmitted from animal to vector to human and anthroponotic VL is 
transmitted from human to vector to human. In the former, human are occasional 
hosts and animals, mainly dogs, are the reservoir of the parasite (3). 
The life-cycle of Leishmania has two distinct forms: the flagellated promastigotes 
found in the gut of the arthropod vector and non-motile amastigotes, which develop 
intracellulary in the mammalian host. Promastigotes injected into the skin during sand 
fly bite are internalized by dendritic cells and macrophages in the dermis where they 
lose their flagella during the differentiation into the amastigote form. They multiply 
and survive within the phagolysosome through complex host-parasite interactions (9, 
10). The incubation period can vary from weeks to months and during this period 
disease symptoms may gradually appear and worsen with disease manifestations 
ranging from self-healing skin lesions to diffuse cutaneous and mucosal 
manifestations and, in some cases, to severe visceral involvement to spleen, liver and 
lymph nodes depending on species of Leishmania and the immune status of the host 
(9, 11). 
 
Fig. 1 Life cycle of Leishmania spp. parasites, adapted from  (12) 
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1.2 Epidemiological data  
 
The epidemiology of leishmaniasis depends on the parasite species involved, the local 
ecological characteristics of the transmission sites, the current and past exposure of the 
human population to the parasite and widely varying human behavior, such as 
socioeconomic factors, malnutrition, environmental changes, population movement and 
climate changes (4). 
Leishmaniasis is one of the world’s most neglected diseases affecting largely the 
poorest of the poor, mainly in developing countries. 350 million people are considered at 
risk of contracting leishmaniasis with an approximate yearly incidence of  1.5-2 million (3, 
12). 
Leishmania species are classified in two different groups: Old World (Mediterranean, 
Middle East and Asian countries) that includes L. major, L. tropica, L. donovani and L. 
infantum, and New World (Latin America) that includes L. chagasi (synonymous with L. 
infantum), L. mexicana, L. amazonensis, L. braziliensis and L. guyanensis (13). 
Leishmaniasis consists of four main clinical syndromes: cutaneous, 
mucocutaneous, visceral and post-kala-azar dermal leishmaniasis (PKDL). Cutaneous 
leishmaniasis (CL) is the most common form of leishmaniasis. CL can be sub-divided 
in Localized Cutaneous Leishmaniasis (LCL) and in Diffuse Cutaneous Leishmaniasis 
(DCL). About 95% of CL cases occur in the Americas, the Mediterranean basin, and the 
Middle East and Central Asia. Over two-third of CL new cases occur in six countries: 
Afghanistan, Algeria, Brazil, Colombia, Iran and Syria. An estimated 0.7 million to 1.3 
million new cases occur worldwide annually  although death cases are rare since CL is 
normally a self-healing condition (14, 15). 
 
Mucocutaneous leishmaniasis leads to partial or total destruction of mucous 
membranes of the nose, mouth and throat. Almost 90% of mucocutaneous 
leishmaniasis cases occurs in the Plurinational State of Bolivia, Brazil and Peru (14, 15). 
 
Visceral leishmaniasis (VL also known as kala-azar) is fatal if left untreated. It 
is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and 
liver and anemia. It is highly endemic in the Indian subcontinent and in East Africa. An 
estimated 200 000 to 400 000 new cases of VL occur worldwide each year. Over 90% 
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of new cases occur in six countries: Bangladesh, Brazil, Ethiopia, India, South Sudan, 
and Sudan (7, 14). 
 
 
Fig. 2 Status of worldwide endemicity of visceral leishmaniasis, 2012, adapted from (16) 
 
In populations where substantial levels of transmission have been sustained over 
periods of years, in endemic areas, a large proportion of the adult population acquired 
immunity to the parasite. Naïve or immunosuppressed adults who enter an endemic area 
are nevertheless at risk of the disease (4). 
Since the early 1990s, the incidence of human leishmaniasis has displayed a large 
increase in Mediterranean countries of southern Europe mainly under the influence of 
human immunodeficiency virus (HIV) infection. In some regions the officially reported 
cases almost doubled between 1997 and 2004, and 25 to 70% of adults with VL are co-
infected with HIV. Further, leishmaniasis is a major public health problem in the eastern 
mediterranean region where cutaneous and visceral leishmaniasis are both endemic (15). 
In Portugal, the Alto Douro region has the highest incidence with 8.3 human 
cases/100000 inhabitants and 12.54% seroprevalence in dogs (14, 17, 18). The 
metropolitan Lisbon region and Algarve have the higher HIV/Leishmania co-infection 
case numbers with 0.2/100000 and 1.2 cases/100000 inhabitants, respectively, but very 
few recent cases among immunocompetent subjects (14, 17, 18).  
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1.3 Clinical presentation 
Leishmaniasis is characterized by a spectrum of clinical manifestations: ulcerative skin 
lesions developing at the site of the sandﬂy bite (localized cutaneous leishmaniasis, LCL); 
multiple non-ulcerative nodules (diﬀuse cutaneous leishmaniasis, DCL); destructive 
mucosal inﬂammation (mucosal leishmaniasis); and disseminated visceral infection 
(visceral leishmaniasis) that can lead to post-kala azar dermal leishmaniasis (PKDL)(12). 
People can carry some species of Leishmania asymptomatically for long periods, 
without becoming ill. In humans, the reported incubation period for cutaneous 
leishmaniasis can be as short as 1-2 weeks or as long as several months when it is caused 
by New World species, and up to three years when Old World species are involved. The 
incubation period for visceral leishmaniasis is 10 days to several years; most cases seem to 
become apparent in two to six months (19, 20). 
 
1.3.1 Cutaneous Leishmaniasis 
  CL usually produces ulcers on the exposed parts of the body, such as the face, arms 
and legs (Fig.3). There may be a large number of lesions – sometimes up to 200 – which 
can cause serious disability. When the ulcers heal, they invariably leave permanent scars, 
which are often the cause of serious social prejudice (21). Of note, leishmaniasis caused by 
visceral species seldom cause cutaneous disease (18, 22).   
 
Fig. 3 Cutaneous leishmaniasis, adapted from (21). 
 
1.3.2 Mucocutaneous Leishmaniasis 
In mucocutaneous leishmaniasis, the lesions can lead to partial or total destruction of 
the mucous membranes of the nose, mouth and throat cavities and surrounding tissues 
(Fig.4). This disabling form of leishmaniasis can lead to the sufferer being rejected by the 
community (23). 
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    Fig. 4 Mucocutaneous Leishmaniasis, adapted from (12) 
 
The clinical spectrum observed in patients indicates the complexity of leishmaniasis 
several Leishmania spp can cause disease (table 1), and many sandﬂy and mammalian 
species have been implicated as vectors and reservoir hosts, respectively (12). 
 
Table 1 Species of Leishmania that cause human disease, adapted from (12) 
 
Main Clinical 
Pathology 
Transmission cycle 
Main geographical 
distribution 
New World Leishmania spp. 
L. brazilliensis LCL, mucosal Zoonotic South America, parts of 
Central America, Mexico 
L. garnhami LCL Zoonotic South America 
Old World Leishmania spp. 
L. major LCL Zoonotic Central Asia, north 
Africa, middle east, East 
Africa 
L. donovani Visceral, LCL Anthroponotic Africa, central Asia, 
southeast Asia 
Old and New World Leishmania spp. 
L. infantum 
=(L.chagasi)(24)  
Visceral, LCL Zoonotic Europe, north Africa, 
Central America, South 
America 
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1.3.3. Visceral Leishmaniasis (VL) 
VL is usually an insidious, chronic disease among the inhabitants of endemic areas; 
however, the onset may be acute in travelers from Leishmania-free areas (Fig.5). In some 
cases (especially in Africa), a primary granuloma appears on the skin at the site of the bite 
before the systemic signs (15, 20). 
The most common symptoms of visceral leishmaniasis are a prolonged undulant 
fever, weight loss, decreased appetite, signs of anemia, and abdominal distension with 
splenomegaly and hepatomegaly. Thrombocytopenia may cause bleeding tendencies, 
including petechiae or hemorrhages on the mucous membranes, and leukopenia can result 
in increased susceptibility to other infections (20). 
 Other symptoms may include coughing, chronic diarrhea, darkening of the skin, 
lymphadenopathy, and in many cases, signs of chronic kidney disease. Mild cases with 
only a few symptoms may resolve spontaneously. Unless VL is treated, the majority of the 
cases are eventually fatal, often from secondary infections and other complications. 
Fulminant disease or atypical cases can also occur, especially in patients co-infected with 
HIV. People with successfully treated infections continue to carry the parasite, and the 
disease may recur if they become immunosuppressed. Similarly, asymptomatically 
infected individuals may later develop clinical signs (12, 19, 20).  
 
Fig. 5 Visceral leishmaniasis. adapted from (14, 25).  
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Post-kala azar dermal leishmaniasis (PKDL) occurs after recovery in some 
cases of visceral leishmaniasis caused by L. donovani (Fig.6). This syndrome is 
characterized by a maculopapular, macular or-nodular rash around the mouth, which 
spreads. In Africa, PKLD is common, usually occurs within 6 months of visceral 
leishmaniasis, and typically disappears within a year without treatment. In South Asia, 
this syndrome is relatively rare, occurs several years after VL has been cured, and required 
prolonged treatment. In India, PKLD is seen in 1-3% of successfully treated cases of 
visceral leishmaniasis (20). 
 
 
Fig. 6 Post-Kala Azar dermal leishmaniasis, adapted from(25). 
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1.4 Reservoir 
The transmission of L. infantum from domestic dogs by the bite of infected sandflies 
was first demonstrated in the 1930s (26, 27). Subsequently, many studies have confirmed 
the role of the domestic dog as the primary reservoir of Zoonotic Visceral Leishmaniasis 
(ZVL): dogs often have long-lasting infections with a high prevalence of both infection and 
infectiousness, being common in the peridomestic environment in which most ZVL 
transmission occurs (11). In infected dogs the disease can present symptoms 
(approximately 45.4%) (fig.7) or not (24.4%), with the latter being more common (28).  
 
There are many Leishmania reservoirs all over the world. In the Americas the most 
common reservoirs are sloths, opossums, small forest rodents such as the hydrax and peri-
domestic dogs (20). In India, the asymptomatic and symptomatic individuals serve as a 
reservoir for the parasite. This is a particularly case of an anthroponotic life cycle where 
only 1 in 7 infected with L. donovani complex become symptomatic (20). 
 
 
Fig. 7  A Dog with visceral leishmaniasis, adapted from (29). 
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II.  Diagnostic methods 
 
The accurate diagnostic of Leishmania infection is a huge challenge because of the 
wide spectrum of clinical manifestations that it may be presented (15). 
Early diagnosis is essential for both individual patients and for the community. Adult 
patients in Sudan with severe anemia, malnutrition and long duration of illness were 
shown to be at an increased risk of death (30). Untreated VL patients act as a reservoir for 
parasites and therefore contribute to disease transmission in anthroponotic VL areas. 
Early case-finding and treatment is therefore considered an essential component of VL 
control (31-33). The concomitant detection and treatment of PKDL patients is also likely 
to be beneficial and the feasibility, impact and cost of a PKDL management strategy 
should therefore be properly evaluated (3). 
As the clinical presentation of VL lacks specificity, confirmatory tests are required to 
decide which patients should be treated. Such tests should be highly sensitive (>95%) as 
VL is a fatal condition, but also highly specific due to the non-pathognomonic 
symptomatology assuring the proper use of anti-Leishmania drugs. Ideally, a test should 
be able to make the distinction between acute disease and asymptomatic infection, 
because none of the drugs currently available is safe enough to treat and follow 
asymptomatic infections. Moreover, such tests should be simple and affordable (3). 
The direct methods include parasite detection and indirect methods can be divided in 
molecular (Polymerase Chain Reaction (PCR) and quantitative Polymerase Chain 
Reaction (qPCR)) and serological (Direct Agglutination Test (DAT), Indirect Fluorescent 
Antibody Test (IFAT), Enzyme Linked Immunosorbent Assay (ELISA), Flow Cytometry 
and nanodiagnostic). 
However, we have non-Leishmania tests that evaluate serological and physiological 
parameters indicatives of Leishmania infection. A reduction in the number of 
erythrocytes, leucocytes and platelets (pancytopenia) was found to be highly specific 
(98%) for VL in suspected clinical patients in Nepal but with low sensitivity (16%) (34). 
Marked polyclonal hypergammaglobulinemia (the production of high titers of non-specific 
antibody), a common finding in VL, can be detected by a formol gel test (FGT; also called 
the aldehyde test), which is still used in East Africa and Asia because of its simplicity and 
low cost. However, as the sensitivity of this test is poor (as low as 34%), and its use has 
been recommended to be discontinued (35, 36). 
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2.1 Direct methods 
 
2.1.1 Parasite detection 
 
The visualization of the amastigote form of the parasite by microscopic 
examination of aspirates from lymph nodes, bone marrow (fig.8) or spleen is the classical 
confirmatory test for VL. Although the specificity is high, the sensitivity of microscopy 
analysis varies, being higher for spleen (93–99%) than for bone marrow (53–86%) or 
lymph node (53–65%) aspirates  (37-41). 
 However, spleen aspiration can be complicated by life threatening hemorrhages in 
~0.1% of individuals and therefore requires considerable technical expertise (7, 42), as 
well as facilities for nursing surveillance, blood transfusion and surgery. Moreover, the 
accuracy of microscopic examination is influenced by the ability of the laboratory 
technician and the quality of the reagents used. The detection of parasites in the blood or 
organs by culture or by using molecular techniques such as PCR is more sensitive than 
microscopic examination but these techniques remain restricted to referral hospitals and 
research centers, despite efforts to simplify them (3, 36, 43). 
 
 
 
 
 
 
Fig. 8 Light-microscopic examination of a stained bone marrow specimen from a 
patient with visceral leishmaniasis—showing a macrophage containing 
multiple Leishmania amastigotes (the tissue stage of the parasite). Note that each amastigote 
has a nucleus (red arrow) and a rod-shaped kinetoplast (black arrow). Visualization of the 
kinetoplast is important for diagnostic purposes, to be confident the patient has leishmaniasis, 
adapted from (1) 
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2.2 Indirect methods  
 
2.2.1 Molecular methods 
 
Molecular parasitological diagnoses have been extensively explored during the past 
decade. It is essentially performed  by PCR based methods and it is particularly useful in 
cases with low parasite burden (12). The detection of Leishmania parasites by PCR 
methods is highly specific and sensitive, with values reaching up 100% (44). However, 
these techniques remain complex and expensive, and in most VL-endemic countries are 
therefore restricted to a few teaching hospitals and research centers (5). 
Molecular approaches have shown great potential for the diagnosis of 
leishmaniasis, follow-up after treatment, disease control and epidemiology.  
 
2.2.1.1 PCR (Polymerase Chain Reaction) 
 
In the last decade, PCR has proved to be a sensitive, specific and powerful tool to 
detect Leishmania DNA. PCR-based assays currently constitute the main molecular 
diagnostic approach of researchers and health professionals (43, 45, 46). 
PCR for amplification of defined parasite DNA sequences is highly sensitive for 
animals with clinical disease. The sensitivity of a PCR assay primarily depends upon three 
factors: the physicochemical conditions of the reaction, the concentration and nature of 
the DNA target, and the selected PCR primers (47-49). 
 Leishmania kinetoplast DNA contains abundant, parasite-specific, repetitive 
sequences (organized in thousands of maxicircles and minicircles) that are very useful as 
targets for nucleic acid-based detection. The PCR assay based on kinetoplast amplification 
is probably the most sensitive because this molecular target is present in about 10 000 
copies per parasite. Conserved regions of Leishmania small-subunit ribosomal RNA (SSU 
rRNA) are also used as PCR target (46, 50, 51). 
In comparison with direct methods, PCR shows more sensitivity in confirming 
asymptomatic infections, which are characterized by low or intermittent parasite. Thus, 
PCR-based methods allow a highly sensitive and specific detection of Leishmania parasite 
even in samples where parasite load is low  (43, 52). 
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The number of positive diagnoses would increase due to parasite detection in patients 
whose smears are negative, and adequate treatment can be applied as early as possible 
(53). PCR targets should be chosen according to the aim to which it is directed. PCR-based 
assays using kinetoplast DNA targets are the most sensitive for the diagnosis of 
leishmaniasis, but they identify Leishmania parasites only to the generic and/or 
subgeneric level, whereas other PCR targeting intergenic regions in nuclear DNA are 
better when rapid and reliable species identification is needed (51). Polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) allowed identification of 
parasites at the complex level. 
However, the technical complexity and access to sophisticated equipment may 
reduce the practicality of the method in developing countries, which in turn are the most 
affected by VL (46, 54). A rapid dipstick test has been developed to overpass these 
limitations named Leishmania OligoC-Test. This test is simplified and it is based on the 
amplification of a small sequence of the 18S rRNA gene, followed by visualization of the 
PCR products on a dipstick by hybridization with a gold-conjugated probe. There is no 
need of expensive equipment or high technology, and so, the OligoC-test can be conducted 
in low-level-equipped laboratories and present a low-cost for the users. This is a very 
important issue in high endemicity locations, where poor population has a limited access 
to appropriate health care (46). This test presents a sensitivity of 96.4% and a specificity of 
88.8% (55). 
 
2.2.1.2 qPCR (quantitative Real-Time Polymerase chain reaction) 
 
This technology has revolutionized the way clinical microbiology laboratories 
diagnose human pathogens, by adding reliability and speed. The combination of  excellent 
sensitivity and specificity, low contamination risk and ease of performance has made 
qPCR technology an appealing alternative to other diagnostic methods (49, 56). 
qPCR can be used to assess host tissue quantification of parasites, which is useful in 
monitoring disease progression. Absolute quantification is determined by comparison to 
standard curves from parasite DNA. When sensitivity must be maximized, namely when 
detection and quantification are needed, high-copy number targets (rRNA genes and 
kinetoplast DNA minicircles) should be chosen the best target. The parasite viability can 
also be demonstrated by qPCR using RNA instead of DNA (43, 50, 52). 
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Real-time qPCR would become the reference technique in the future because it is more 
rapid and less prone to contamination (no post-PCR handling is required), although, when 
compared with conventional PCR, the cost can be 3 fold higher (56). 
As the choice of the PCR assay will depend on the aim of the test, the choice of the target, 
evaluation of the cost/benefit has to be done (51). 
 
2.2.2 Serological diagnosis 
 
The use of antigens for the serodiagnosis of tropical diseases is often limited by the 
difficulty in producing large quantities of the antigen (7, 57). However, serodiagnosis is 
easy to perform, cheap to make and has both high specificity and sensibility depending on 
the antigen (57). 
 
2.2.2.1 DAT (Direct Agglutination Test) 
 
In 1985, El Harith et al. developed a DAT for VL with high sensitivity and 
specificity (58). This test is semi-quantitative and uses microtitre plates with V-shaped 
wells in which increasing dilutions of serum or blood eluted from filter paper are mixed 
with stained killed L. donovani promastigotes. 
Since 1986, the DAT has been extensively validated in most VL-endemic areas. 
Thirty studies were included in a recent meta-analysis, showing sensitivity and specificity 
estimates of 94.8% (95% confidence intervals (CI), 92.7–96.4) and 97.1% (95% CI, 93.9– 
98.7), respectively (59). The DAT performance was neither dependent on the region nor 
on the Leishmania species. DAT antigen production was initiated in some endemic 
countries but the production could not always be sustained, and quality control remained 
an issue. The cost of the antigen is in the range of 1–2EUR/test.  Although highly sensitive 
and specific, the DAT requires substantial manipulation, and can only be read after a 
minimum of 8 hours incubation (5). Moreover, a multi-center study reported low 
reproducibility owing to problems reading the results and the heat- and shock sensitivity 
of the liquid antigen (60). 
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2.2.2.2 ELISA (Enzyme linked immunosorbent assay) 
 
Enzyme linked immunosorbent assay (ELISA) has been used in the serodiagnosis 
of VL. ELISA is the best choice for the development of a rapid and reliable diagnostic 
method, because it is more practical, easy to standardize and suitable for mass screening 
(6). However, sensitivity and specify of ELISA depends upon the antigen used (36). 
Previously, the following proteins,  HSP83, hsp70, RkLO8, rK26, rK9, SIR2, , 
LicTXNPx, rK39 and rK28, have been individually studied and a combination named LAM 
(LicTXNPx+rK39) was previously reported (6, 45). Soluble Leishmania antigens 
(SLA) are produced from the promastigote stage of L. infantum. SLA are the most 
commonly used antigens in ELISA. These ELISAs have demonstrated sensitivities and 
specificities of 80 to 100% and 85 to 95%, respectively (61). However, the use of SLA and 
occurrence of false positive results in cases of Chagas disease have been documented (62-
66).The use of total soluble antigens is limited due to problems of reproducibility and 
manufacturing (45). 
Leishmania infantum cytosolic tryparedoxin peroxidase (LicTXNPx) 
antigen, is a member of unique enzymatic Leishmania cascades for detoxification of 
peroxides (67), as a highly immunogenic probe during natural human or experimental 
canine infectious. ELISA test based on LicTXNPx presented a sensitivity of 78.6% and a 
specificity of 89.0% in the detection of CVL (45). 
Recombinant K39 antigen (rK39) is a 39-amino-acid repetitive 
immunodominant B-cell epitope of the 230kDa kinesin related protein of L. chagasi 
(LcKin).(68, 69). ELISA test based on LicTXNPx presented a sensitivity of 93.5% and a 
specificity of 92.38% (9). An immunochromatographic strip test with 
recombinant k39 antigen (rk39 ICT) was developed (70). The InBios Kalazar Detect 
rapid test utilizes the recombinant L. chagasi antigen rK39(69). It has previously been 
reported that L. chagasi, L. donovani, and L. infantum all contain the gene encoding the 
LcKin protein (69). A membrane strip containing a conjugate dye region is coated with 
this protein. Through capillary action, the patient serum will react with the dye and 
antigen to quickly indicate the presence of anti-rK39 immunoglobulin G (IgG) in a patient 
sample (70). 
 It is easy to use in the field and results are available after 15 minutes. The initial 
study showed 100% sensitivity and 98% specificity (71), but this particular format (Arista 
Biologicals, Allentown, PA, USA) is no longer commercially available because several 
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limitations  (71). First, additional field testing of the impregnated strip in other parts of the 
world where kala-azar is endemic is needed to confirm the applicability of our findings. 
Second, firm diagnoses of other diseases were not reached in some of our strip-test 
negative patients. An evaluation in Sudan of ICT from the same producer showed only 
67% of sensitivity (72). An ICT produced by a different company (INBIOS, Seattle, WA, 
USA) proved to be a good diagnostic guide in suspected VL cases in India(73) and in 
Bangladesh.  Sarker et al. found excellent sensitivity (96.6%) and specificity (98.3%) with 
this ICT (74). In Nepal, an early prototype showed a specificity of only 71% in controls with 
clinical signs of VL (75); however, better specificity (above 90%) was obtained with later 
generations of the InBios ICT and with an ICT produced by DiaMed AG, Switzerland (34, 
76). 
 
Recombinant K28 antigen (rK28) is a fusion polyprotein comprising regions of 
L. donovani haspb1 (L. infantum k26 homologue), L. donovani kinesin (L. infantum k39 
homologue) and L. donovani haspb2 (L. infantum K9 homologue) (7, 9). The ELISA tests 
based on these antigens have shown sensitivities of 88.4-99.6% and specificity 90.53-
98.95% (9). 
Rk28 ELISA is more sensitive and specific than rk39, and have a high predict diagnostic 
accuracy than rk39 (9). 
The presence of parasite antigens released in urine can be linked to the level 
of renal physiology as well as status of infection present in the host. In addition, the 
urinary antigens may be also useful in diagnostic and prognostic purposes (77). The 
diagnostic capabilities of urinary antigens have been reported in various infectious 
diseases like schistosomiasis (78), malaria (79), Chagas disease and river blindness. The 
presence of soluble urinary Leishmania antigens in VL has been successfully reported in 
various studies (77, 80), however, their characterization has not been done in most of the 
cases (80). In the context to unavailability of a perfect diagnostic and prognostic tool, the 
urinary Leishmania antigens offer a better prospective (77).  
 Recently, in Sudan and other countries, a new latex agglutination test (KAtex; 
Kalon Biological, UK) for detecting Leishmania antigen in urine was evaluated in patients 
suspected to have VL(81). In urine, KAtex detects a low-molecular-weight glycoconjugate 
(5–20 kDa) that is present in the promastigote and amastigote stages of the parasite (82). 
Antigen detection in urine (ADU) by KAtex is quick and easy to perform. The use of urine 
over other conventional samples taken for VL diagnosis offers an advantage in that urine 
is easy to obtain; moreover, ADU is highly sensitive during clinical episodes. Therefore, 
ADU is appropriate for diagnosis of primary VL, for monitoring the efficacy of treatment, 
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and for detection of subclinical infection. From a clinical standpoint, a positive ADU result 
in the absence of symptoms is a marker of the parasite’s presence but not necessarily of 
the disease (81). ADU presents a high sensitivity in the diagnosis of VL during primary 
episodes (42/49, 84.6%) and relapses (16/18, 88.8%) when the parasite load is high (81). 
 
2.2.2.3 IFAT (Indirect Fluorescence Antibody Test) 
 
 Fluorescent antibody techniques are extremely valuable qualitative tolls but they 
do not provide quantitative data. IFAT is a semi-quantitative assay that allows evaluation 
of anti-Leishmania antibody titers produced by infected individuals (83, 84). 
 On the other hand, the interpretation of IFAT may be subjective, dependent on the skill of 
the operator, and although the specificity and sensitivity can be high (100% and 90% 
respectively), in respect to asymptomatic infections IFAT has sensitivity significant lower 
than rk39 ELISA test (83, 85). 
 
2.2.2.4 Flow cytometry 
 
The use of flow cytometry for the serodiagnosis of leishmaniasis was initiated by a 
study that evaluated the presence of antibodies against L. brazilliensis promastigotes (86). 
Subsequently, the same approach was adapted for determining anti-L. infantum antibody 
levels in serum samples from dogs with CVL (87). Recently, the applicability of flow 
cytometry serology as a novel assay for diagnosis of CVL was reported, and this method 
showed great sensitivity (95%) and specificity (100%) for CVL diagnosis (88, 89).  
A new method was developed based on flow cytometric analysis since this 
technology is considered to be highly sensible and specific for the diagnosis of infectious 
diseases (90). This method combines antigen-coated magnetic microspheres, 
immunomagnetic separation and flow cytometry for the detection of specific antibodies to 
Leishmania (91). 
This technique possesses several advantages for immunoassays such as high throughput 
capacity, possibility of analyze quantification, reduced sample volume, high 
reproducibility and sensitivity, a wide dynamic range, and, the most exciting to all, the 
potential for multiplexing (90).  
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2.2.2.5 Nanodiagnostic 
 
Micro and nanotechnology have been applied in the development of biosensors 
that emerge as promising diagnostic methods (92). Microsphere-based immunoassay with 
covalent binding between an antigen or antibody to magnetic microspheres have been 
considered promising alternatives for serological analysis (93). 
The use of nanotechnologies for diagnostic applications shows great promise to 
meet the rigorous demands of the clinical laboratory for sensitivity and cost-effectiveness. 
Nanodiagnostic not only aims to meet the demands of clinical diagnostic for increased 
sensitivity, but also pretends to achieve an early detection of the disease. The fact that 
most nanotechnology-based assays are perfectly adaptable to automation, and do not 
require a separation test, makes them diagnostic tools very appealing for scientists and 
clinicians (94). 
Nanotechnology promises to play an important role in the future development of 
diagnostic and therapeutic methods. Whether nanodiagnostics will replace current 
diagnostic methods remains to be proved. Many aspects of these nanodiagnostics 
techniques need to be evaluated further, especially the safety issues (94, 95). 
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